Rapid Dose Therapeutics Corp. has secured government funding of $400,000 from The National Research Council of Canada Industrial Research Assistance (NRC-IRAP), to support a project focused on commercial development and scale-up manufacturing of cannabis infused QuickStrip™ oral dissolvable film strips. The funding will help RDT augment product development as well as enhance its manufacturing competency while creating new jobs and training skilled technical employees.
“This grant funding award from NRC-IRAP will help support speed to market for RDT’s QuickStrip™ products and enable scale production capacity to supply global markets, demonstrate superior product performance for customers while strengthening the Company’s IP portfolio,” said Mark Upsdell, CEO and Founder of RDT. He further added, “We are honoured and grateful to receive funding support from the Canadian government to help us advance our business innovation and commercialization activities.”
Rapid Dose Therapeutics Corp. is a publicly traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers.